Is Velpatasvir compatible with breastfeeding? Do we have alternatives for Velpatasvir?

Velpatasvir

August 6, 2017 (Low Risk)

Usually used in combination with sofosbuvir in the treatment of hepatitis C.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (high molecular weight and very high percentage of protein binding) make it very unlikely that significant amounts would pass into breast milk, therefore it would not be necessary to stop breastfeeding when taking this medication on its own or in combination with sofosbuvir (Lactmed 2016).


See below the information of these related products:

Alternatives

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Writings

  • فالباتاسفير (Arabic)
  • Велпатасвир (Cyrillic)
  • 维帕他韦 (Chinese)
  • C49H54N8O8 (Molecular formula)
  • GS-5816 (Experimental code/s)

Drug trade names

References

  1. EMA. Sofosbuvir/Velpatasvir (Epclusa). Ficha técnica. 2017 Full text (in our servers)
  2. EMA. Sofosbuvir/Velpatasvir (Epclusa). Drug Summary. 2017 Full text (in our servers)
  3. LactMed. Velpatasvir. Full Record Display. 2016 Full text (in our servers)